Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast Cancer

Fred C. Kass, MD
Published: Friday, Aug 28, 2015



Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.

The field of HER2-positive breast cancer is one which oncologists are gratified by the amount of treatments available to patients, Kass explains. There has been great success with adjuvant treatments, as well as personalized medicine.

However, the variation of treatments can be a drawback, as there is uncertainty on when and how to use all of the therapies. Therefore, Kass says, oncologists have not yet determined optimal treatment sequencing for HER2-positive breast cancer.



Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.

The field of HER2-positive breast cancer is one which oncologists are gratified by the amount of treatments available to patients, Kass explains. There has been great success with adjuvant treatments, as well as personalized medicine.

However, the variation of treatments can be a drawback, as there is uncertainty on when and how to use all of the therapies. Therefore, Kass says, oncologists have not yet determined optimal treatment sequencing for HER2-positive breast cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x